<DOC>
	<DOCNO>NCT00680186</DOCNO>
	<brief_summary>The general aim study determine comparative safety efficacy dabigatran etexilate 150 mg bid administer orally warfarin Pro nata ( As needed/PRN ) maintain International Normalised Ratio ( INR ) 2.0-3.0 6 month treatment acute symptomatic VTE . The primary objective investigate efficacy dabigatran compare warfarin 6 month treatment period . The investigation select efficacy aspect safety regard secondary objective trial .</brief_summary>
	<brief_title>Phase III Study Testing Efficacy &amp; Safety Oral Dabigatran Etexilate v Warfarin 6 Treatment Acute Symp Venous Thromboembolism ( VTE )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Acute symptomatic uni bilateral Deep Vein Thrombosis ( DVT ) leg involve proximal vein , and/or Pulmonary Embolism ( PE ) Male female , 18 year age old Written inform consent study participation Exclusion criterion : Persistent symptom VTE PE require urgent intervention Use vena cava filter Contraindications anticoagulant therapy Allergy study medication Elevated Aspartateaminotransferase ( AST ) Alanineaminotransferase ( ALT ) &gt; 3x Upper Limit Normal ( ULN ) know liver disease expect impact survival Severe renal impairment Patients consider unsuitable inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>